3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
32
NETWORK
6
OTHER_GOV
4
NIH
3
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
15
CNS
10
Gastrointestinal
8
Thoracic
6
Genitourinary
4
Dermatologic
3
Head & Neck
2
Tumor-Agnostic
1
NET
1
Gynecologic
1
Endocrine
1
Conditions
Uterine Cervical Neoplasms
1
Neoplasm Metastasis
1
Interventions
Paclitaxel
192
Carboplatin
159
pembrolizumab
118
Bevacizumab
86
liposomal doxorubicin
68
Gemcitabine
62
Cisplatin
55
olaparib
49
Topotecan
47
Nivolumab
32
niraparib
30
Cyclophosphamide
30
Doxorubicin
29
Docetaxel
26
1-dodecylpyridoxal
22
Injections
21
Drug Therapy
20
human papillomavirus vaccine, L1 type 16, 18
19
fludarabine
18
atezolizumab
18
Pemetrexed
18
lenvatinib
17
mirvetuximab soravtansine
16
Fulvestrant
16
avelumab
15
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
15
durvalumab
14
Oxaliplatin
13
Irinotecan
13
Fluorouracil
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Surgical Procedures, Operative
×
Gynecologic
×
Clear all
NCT05081609
2026-02-24
IL Believe
Ascendis Pharma A/S
Phase 1/2
Active not recruiting
320 enrolled